OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

References

• Finn OJ, Beatty PL. Cancer immunoprevention. Curr Opin Immunol. 2016;39:52–58. doi:10.1016/j.coi.2016.01.002. PMID:26799207.
   PubMed Web of Science ®Google Scholar
• Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001;194(9):1195–205. doi:10.1084/jem.194.9.1195. PMID:11696586.
   PubMed Web of Science ®Google Scholar
• De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 2004;64(11):4001–9. doi:10.1158/0008-5472.CAN-03-2984. PMID:15173014.
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer. 2006;6(3):204–16. doi:10.1038/nrc1815. PMID:16498443.
   PubMed Web of Science ®Google Scholar
• Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol. 2004;173(4):2288–96. doi:10.4049/jimmunol.173.4.2288. PMID:15294941.
   PubMed Web of Science ®Google Scholar
• Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res. 2010;70(20):7755–63. doi:10.1158/0008-5472.CAN-10-0701. PMID:20924100.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7. doi:10.1016/j.coi.2013.12.005. PMID:24413387.
   PubMed Web of Science ®Google Scholar
• Jacob JB, Kong YC, Meroueh C, Snower DP, David CS, Ho YS, Wei WZ. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res. 2007;67(14):7020–7. doi:10.1158/0008-5472.CAN-06-4755. PMID:17638915.
   PubMed Web of Science ®Google Scholar
• Weiss VL, Lee TH, Jaffee EM, Armstrong TD. Targeting the right regulatory T-cell population for tumor immunotherapy. Oncoimmunology. 2012;1(7):1191–3. doi:10.4161/onci.20664. PMID:23170276.
   PubMed Web of Science ®Google Scholar
• Nair RE, Kilinc MO, Jones SA, Egilmez NK. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol. 2006;176(12):7325–34. doi:10.4049/jimmunol.176.12.7325. PMID:16751376.
   PubMed Web of Science ®Google Scholar
• Linch SN, McNamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol. 2015;5:34. doi:10.3389/fonc.2015.00034. PMID:25763356.
   PubMed Web of Science ®Google Scholar
• Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer. 2016;52:50–66. doi:10.1016/j.ejca.2015.08.021. PMID:26645943.
   PubMed Web of Science ®Google Scholar
• Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7(11):880–7. doi:10.1038/nrc2250. PMID:17957190.
   PubMed Web of Science ®Google Scholar
• Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 2008;205(4):825–39. doi:10.1084/jem.20071341. PMID:18362171.
   PubMed Web of Science ®Google Scholar
• Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 2008;68(13):5206–15. doi:10.1158/0008-5472.CAN-07-6484. PMID:18593921.
   PubMed Web of Science ®Google Scholar
• Burocchi A, Pittoni P, Gorzanelli A, Colombo MP, Piconese S. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur J Immunol. 2011;41(12):3615–26. doi:10.1002/eji.201141700. PMID:22229156.
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92(6):475–80. doi:10.1038/icb.2014.26. PMID:24732076.
   PubMed Web of Science ®Google Scholar
• Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, Lustgarten J. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer. 2005;116(6):934–43. doi:10.1002/ijc.21098. PMID:15856473.
   PubMed Web of Science ®Google Scholar
• Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol. 2006;176(2):974–83. doi:10.4049/jimmunol.176.2.974. PMID:16393983.
   PubMed Web of Science ®Google Scholar
• Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, Jaffee EM, Tani T. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer. 2009;125(3):630–8. doi:10.1002/ijc.24435. PMID:19455675.
   PubMed Web of Science ®Google Scholar
• Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A. 2016;113(3):E319–27. doi:10.1073/pnas.1510518113. PMID:26729864.
   PubMed Web of Science ®Google Scholar
• Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW, Jr., Emens LA. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunol Res. 2017;5(6):468–79. doi:10.1158/2326-6066.CIR-16-0284. PMID:28483787.
   PubMed Web of Science ®Google Scholar
• Curti A, Parenza M, Colombo MP. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood. 2003;101(2):568–75. doi:10.1182/blood-2002-03-0991. PMID:12393660.
   PubMed Web of Science ®Google Scholar
• Shibahara I, Saito R, Zhang R, Chonan M, Shoji T, Kanamori M, Sonoda Y, Kumabe T, Kanehira M, Kikuchi T, et al. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Mol Cancer. 2015;14:41. doi:10.1186/s12943-015-0307-3. PMID:25744203.
   PubMed Web of Science ®Google Scholar
• Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014;2(3):194–9. doi:10.1158/2326-6066.CIR-13-0214. PMID:24778315.
   PubMed Web of Science ®Google Scholar
• Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, Di Pierro F, De Giovanni C, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol. 1995;155(6):3112–23. PMID:7673726.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu JQ, Talebian F, Liu Z, Yu L, Bai XF. IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology. 2015;4(7):e1014232. doi:10.1080/2162402X.2015.1014232. PMID:26140236.
   PubMed Web of Science ®Google Scholar
• Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res. 2008;68(13):5423–31. doi:10.1158/0008-5472.CAN-07-6436. PMID:18593945.
   PubMed Web of Science ®Google Scholar
• Ruby CE, Weinberg AD. OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol. 2009;182(3):1481–9. doi:10.4049/jimmunol.182.3.1481. PMID:19155495.
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–8. doi:10.1158/1078-0432.CCR-16-1741. PMID:27827313.
   PubMed Web of Science ®Google Scholar
• Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S, Tartour E. Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel). 2016;4(4):37. PMID:27827885.
   PubMed Web of Science ®Google Scholar
• Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clin Cancer Res. 2017;23(20):6165–77. doi:10.1158/1078-0432.CCR-16-2677. PMID:28855348.
   PubMed Web of Science ®Google Scholar
• Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R. Eradication of spontaneous malignancy by local immunotherapy. Sci Transl Med. 2018;10(426) doi:10.1126/scitranslmed.aan4488.
   PubMed Web of Science ®Google Scholar